Sign in
Active, not recruitingPhase 2

PiSCATIN - Simvastatin for the treatment of primary sclerosing cholangitis (PSC) - a randomized double-blind, placebo-controlled multicenter study

Key facts

Who runs it
Karolinska University Hospital
Where
Sweden12 sites in 1 countryChoose a country to see its sites
Status
Active, not recruiting
Phase
Phase 2
People taking part
560 people, planned
Started
4 May 2020
Expected to end
30 Sept 2030
Type of study
Interventional
Record updated
9 January 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (15)Hide the full registry criteria

Who can take part

  • Patients with a cholangiographically verified PSC and/or liverbiopsy with and without IBD (patients with a present autoimmun hepatit and small duct PSC can be included)
  • Men and women ≥18 years but ≤75 years
  • Patient has given written consent to participate in the study
  • MR/MRCP within 4 months
  • Coloscopy within 24 months if the patient has a known IBD
  • Female of childbearing potential must agree to use a highly efficient method of contraception during the study participation

Who cannot take part

  • Patients on waiting list for transplantation
  • Previous varices bleeding secondary to end stage liver disease
  • Previous cholangiocarcinoma
  • Patients who have been taking any statin medication during the last 3 months
  • Patients with severe liver failure ≥ Child B 9 points
  • Transplanted patients
  • Patients with secondary sclerosing cholangitis
  • Intolerance to statins
  • Pregnancy and breastfeeding

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Does treatment with simvastatin prolong survival free from bile duct cancer, variceal bleeding and transplantation in PSC?

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
9 January 2026